Rapidly progressive and metastatic mucoepidermoid carcinoma: application of serological tumor markers.
Mucoepidermoid carcinoma (MEC) of the salivary gland is a rare entity. A distinction of 2 variants has been proposed: the low-grade tumor with a favourable prognosis and the high-grade tumor with a poor prognosis. Indeed, MEC is a cancer with a relative favourable outcome and more than 90% of patients survive for more than 5 years after diagnosis, reduced to about 70% after 10 years. This excellent prognosis might contribute to the unacceptable retention of the term "mucoepidermoid tumor" in the medical terminology, even in current medical textbooks. However, the distinction of MEC by grading is a guideline only and it is not appropriate to use this histological term as a prediction for individual cases. We describe the rapid fatal outcome of a patient with MEC in order to emphasize the malignant characteristics of this tumor and the possible application of tumor markers for the diagnosis of metastasizing MEC.
Friedrich
Reinhard E
RE
Maxillofacial Surgery, Eppendorf University Hospital, University of Hamburg, Hamburg, Germany. rfriedri@uke.uni-hamburg.de
Klapdor
Rainer
R
Bartel-Friedrich
Sylva
S
D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000556:secondary; D018277:Carcinoma, Mucoepidermoid / Q000097:blood* / Q000473:pathology / Q000503:physiopathology; D018450:Disease Progression; D017809:Fatal Outcome; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D012468:Salivary Gland Neoplasms / Q000097:blood* / Q000473:pathology / Q000503:physiopathology; D012470:Salivary Glands, Minor / Q000473:pathology
D014408:Biomarkers, Tumor